Cutting edge contraception

Basic research zeroes in on sperm and egg development

Written byTom Hollon
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

We have The Pill. Do we really need new contraceptives? Yes, said Allan Rosenfield, dean of the School of Public Health at Columbia University, as he introduced an international symposium to survey New Frontiers in Contraceptive Research, held July 15–16 in Washington, D.C.

In a world where 40 to 60% of pregnancies are estimated to be unwanted, where as many as 200 million women worldwide have unmet needs for contraceptives, and where men have only condoms and vasectomy, there is an emphatic need for new approaches to contraception. Yet R&D in the pharmaceutical industry "lost its energy" years ago, Rosenfield lamented.

Most drug companies abandoned R&D completely as more than 50 oral contraceptive brands saturated the market. Worry about liability lawsuits if new contraceptives have side effects continues to hinder research, as does the desire to avoid the politics of abortion symbolized by the post-coitus pill RU486 (mifepristone).

So hope ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies